文献速递细菌感染、耐药与抗菌药物

耐药指导的生殖支原体感染序贯治疗结局:一项前瞻性评估

Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation.
PubMed 文献 · Clin Infect Dis · 2019-01-01

2016年墨尔本性健康中心将非淋菌性尿道炎、宫颈炎和直肠炎的推测治疗从阿奇霉素改为多西环素,随后根据大环内酯耐药突变检测结果序贯给予阿奇霉素或西他沙星。244例可评估感染中,大环内酯耐药突变检出率为68.4%,MRM阴性者微生物学治愈率为94.8%,MRM阳性者为92.2%,仅2.6%的大环内酯敏感感染出现耐药选择。

要点

  • 多西环素治疗后根据大环内酯耐药突变检测结果序贯治疗,MRM阴性者治愈率94.8%,MRM阳性者92.2%。
  • 大环内酯耐药突变检出率为68.4%(95%CI 62.2%-74.2%)。
  • 仅2.6%的大环内酯敏感感染出现大环内酯耐药选择。

核心结论

  • 在高水平抗菌药物耐药背景下,将生殖支原体推测治疗从阿奇霉素改为多西环素后序贯耐药指导治疗,治愈至少92%的感染,且大环内酯耐药选择不常见。

研究设计与样本

  • 前瞻性评估,2016年年中墨尔本性健康中心将非淋菌性尿道炎、宫颈炎和直肠炎的推测治疗从阿奇霉素改为多西环素(100 mg,每日两次,共7天)。
  • 病例通过聚合酶链反应检测生殖支原体及大环内酯耐药突变。
  • 多西环素治疗后立即给予MRM阴性感染阿奇霉素2.5 g(1 g,随后500 mg每日一次共3天),MRM阳性感染给予西他沙星(100 mg每日两次共7天)。
  • 在第二种抗生素后14-90天评估治愈试验和再感染风险。
  • 共244例可评估生殖支原体感染(52例女性、68例异性恋男性、124例男男性行为者),诊断时间为2016年6月20日至2017年5月15日。

主要发现

  • 167例(68.4% [95%CI 62.2%-74.2%])检出大环内酯耐药突变。
  • 多西环素治疗使细菌载量平均下降2.60 log10(n=56;P<.0001)。
  • MRM阴性感染中73/77例(94.8% [95%CI 87.2%-98.6%])达到微生物学治愈,MRM阳性感染中154/167例(92.2% [95%CI 87.1%-95.8%])达到微生物学治愈。
  • 大环内酯敏感感染中仅2/76例(2.6% [95%CI .3%-9.2%])出现大环内酯耐药选择。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rising macrolide and quinolone resistance in Mycoplasma genitalium necessitate new treatment approaches. We evaluated outcomes of sequential antimicrobial therapy for M. genitalium guided by a macrolide-resistance assay. METHODS: In mid-2016, Melbourne Sexual Health Centre switched from azithromycin to doxycycline (100 mg twice daily for 7 days) for nongonococcal urethritis, cervicitis, and proctitis. Cases were tested for M. genitalium and macrolide-resistance mutations (MRMs) by polymerase chain reaction. Directly after doxycycline, MRM-negative infections received 2.5 g azithromycin (1 g, then 500 mg daily for 3 days), and MRM-positive infections received sitafloxacin (100 mg twice daily for 7 days). Assessment of test of cure and reinfection risk occurred 14-90 days after the second antibiotic. RESULTS: Of 244 evaluable M. genitalium infections (52 women, 68 heterosexual men, 124 men who have sex with men) diagnosed from 20 June 2016 to 15 May 2017, MRMs were detected in 167 (68.4% [95% confidence interval {CI}, 62.2%-74.2%]). Treatment with doxycycline decreased bacterial load by a mean 2.60 log10 (n = 56; P < .0001). Microbiologic cure occurred in 73 of 77 MRM-negative infections (94.8% [95% CI, 87.2%-98.6%]) and in 154 of 167 MRM-positive infections (92.2% [95% CI, 87.1%-95.8%]). Selection of macrolide resistance occurred in only 2 of 76 (2.6% [95% CI, .3%-9.2%]) macrolide-susceptible infections. CONCLUSIONS: In the context of high levels of antimicrobial resistance, switching from azithromycin to doxycycline for presumptive treatment of M. genitalium, followed by resistance-guided therapy, cured ≥92% of infections, with infrequent selection of macrolide resistance.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Read TRH, Fairley CK, Murray GL, et al. Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation. Clin Infect Dis. 2019. PMID: 29873691. doi:10.1093/cid/ciy477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。